Integrated preclinical development services and platform technologies for tox testing and cell line engineering
2006
Bengaluru (India)
Series C
Anthem Biosciences is a prominent Contract Research and Innovation Service Provider (CRISP) based in Bangalore, India. Established in 2007, the company has rapidly evolved into a key player in drug development and research services, offering a wide range of capabilities to pharmaceutical, biotechnology, and specialty chemicals industries.
Services Offered
Anthem Biosciences provides comprehensive services across various domains:
Chemistry Services:
Medicinal Chemistry
Library Design and Synthesis
Process Development and Custom Synthesis
GMP Manufacturing from milligram to kilogram scale
Molecular Biology
DMPK (Drug Metabolism and Pharmacokinetics)
Microbiology and Pharmacology
Preclinical services with GLP & AAALAC accreditation
Offers end-to-end services from concept to IND (Investigational New Drug) filing, allowing clients to streamline their research processes.
Development of patented tools for preclinical drug discovery, including diagnostic assays for toxicity testing.
The product arm focused on nutraceuticals and dietary supplements, providing innovative products supported by scientific studies.
A division dedicated to branded formulations in diabetology and nephrology, focusing on safe and extensively tested products.
Anthem Biosciences operates on various business models such as FTE (Full-Time Equivalent) and FFS (Fee for Service), allowing flexibility to meet client needs based on project complexity.
The company adheres to stringent regulatory standards, ensuring high-quality service delivery. Their facilities are designed to comply with cGMP regulations, and they maintain robust EHS (Environmental Health and Safety) policies.
Anthem has recently expanded its laboratory space, doubling its capacity with new facilities for in-vivo studies, ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) testing, and fermentation processes.
Anthem Biosciences stands out as a top-tier Contract Research Organization (CRO) due to its experienced team, comprehensive service offerings, and commitment to quality. The company continues to innovate in the drug discovery space while providing reliable support for clients across various sectors within the life sciences industry.
$35.7Million
4
$33.4Million, Series C
as of March 1, 2021
$997Million
as of N/A
2.39
as of N/A
Portsmouthtechnologiestrialsunit
and 4 more2070
Vectura
-
Date | Round Name | Amount | Valuation | Revenue | Revenue Multiple | Investors |
---|---|---|---|---|---|---|
March 1, 2021 | Series C | $33.4Million | $999.0Million | $154.0Million | 6.1x | True North ,Khaitan, o3 Capital, MD&T Partners |
November 14, 2016 | Seed | $1.7Million | $30.9Billion | $52.0Million | 607.7x | Co Portsmouthtechnologiestrialsunit |
May 29, 2008 | Seed | $577.0K | $12.0Million | - | - | Portsmouthtechnologiestrialsunit |